blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3922630

EP3922630 - BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  17.06.2022
Database last updated on 09.04.2026
FormerThe application has been published
Status updated on  12.11.2021
Most recent event   Tooltip14.03.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
Capella Therapeutics, Inc.
3210 Merryfield Row
San Diego, CA 92121 / US
[2021/50]
Inventor(s)01 / LONG, Yun
San Diego, 92127 / US
 [2021/50]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/50]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
Application number, filing date21173958.619.03.2015
[2021/50]
Priority number, dateUS201461968225P20.03.2014         Original published format: US 201461968225 P
[2021/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3922630
Date:15.12.2021
Language:EN
[2021/50]
Search report(s)(Supplementary) European search report - dispatched on:EP13.10.2021
ClassificationIPC:C07D401/14, C07D405/14, C07D409/14, C07D403/04, C07D403/14, C07D403/12, C07D223/04, A61P35/00, A61P43/00, A61K31/55
[2021/50]
CPC:
C07D409/14 (EP,IL,KR,RU,US); C07D401/14 (EP,IL,KR,RU,US); A61K31/4184 (RU);
A61K31/55 (IL,KR,RU,US); A61K31/551 (KR); A61P35/00 (EP,IL,KR,RU);
A61P43/00 (EP); C07D223/04 (US); C07D403/04 (RU,US);
C07D403/12 (US); C07D403/14 (KR,RU,US); C07D405/14 (EP,IL,KR,RU,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/29]
Former [2021/50]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:BENZIMIDAZOLDERIVATE ALS ERBB-TYROSINKINASEHEMMER ZUR BEHANDLUNG VON KREBS[2021/50]
English:BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER[2021/50]
French:DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE ERBB POUR LE TRAITEMENT DU CANCER[2021/50]
Examination procedure15.06.2022Examination requested  [2022/29]
15.06.2022Date on which the examining division has become responsible
08.07.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
06.09.2022Amendment by applicant (claims and/or description)
Parent application(s)   TooltipEP15717994.6  / EP3119762
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
06.09.2022Request for further processing filed
06.09.2022Full payment received (date of receipt of payment)
Request granted
16.09.2022Decision despatched
Fees paidRenewal fee
14.05.2021Renewal fee patent year 03
14.05.2021Renewal fee patent year 04
14.05.2021Renewal fee patent year 05
14.05.2021Renewal fee patent year 06
14.05.2021Renewal fee patent year 07
28.03.2022Renewal fee patent year 08
27.03.2023Renewal fee patent year 09
27.03.2024Renewal fee patent year 10
13.03.2025Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] WO2014036016  (PRINCIPIA BIOPHARMA INC et al.)
 [A] WO2013184757  (IRM LLC et al.)
 [A] WO2013184766  (IRM LLC et al.)
by applicantUS4328245
 US4409239
 US4410545
 US6350458
 US3845770
 US3916899
 US3536809
 US3598123
 US4008719
 US5674533
 US5059595
 US5591767
 US5120548
 US5073543
 US5639476
 US5354556
 US5639480
 US5733566
 US5739108
 US5891474
 US5922356
 US5958458
 US5972891
 US5980945
 US5993855
 US6045830
 US6087324
 US6113943
 US6197350
 US6248363
 US6264970
 US6267981
 US6270798
 US6375987
 US6376461
 US6419961
 US6589548
 US6613358
 US6623756
 US6699500
 US6793936
 US6827947
 US6902742
 US6958161
 US7255876
 US7416738
 US7427414
 US7485322
 US5798119
 US5612059
 US5698220
 WO0217918
 US5709874
 US5759542
 US5840674
 US5900252
 US5972366
 US5985307
 US6004534
 US6039975
 US6048736
 US6060082
 US6071495
 US6120751
 US6131570
 US6139865
 US6253872
 US6271359
 US6274552
 US6316652
 US7169410
 US5323907
 US5052558
 US5033252
   YARDEN ET AL., NAT. REV. MOL. CELL. BIOL., vol. 2, 2001, pages 127 - 137
   HYNES ET AL., NAT. REV. CANCER, vol. 5, 2005, pages 341 - 354
   NICHOLSON ET AL., EUR. J. CANCER, vol. 37, 2001, pages 9 - 15
   SLAMON ET AL., SCIENCE, vol. 235, 1997, pages 177 - 182
   HUDIS, N. ENGL. J. MED., vol. 357, 2007, pages 39 - 51
   CIARDIELLO ET AL., N. ENGL. J. MED., vol. 358, 2008, pages 1160 - 1174
   GRADISHAR, N. ENGL. J. MED., vol. 366, 2012, pages 176 - 178
   SHARMA ET AL., NAT. REV. CANCER, vol. 7, 2007, pages 169 - 181
   LANGER, J. CLIN. ONCOL., vol. 31, 2013, pages 3303 - 3330
   ERION ET AL., J. PHARMACOL. EXP. THER., vol. 312, 2005, pages 554 - 560
   "The Pharmaceutical Press and the American Pharmaceutical Association", 2012
   J. ORG. CHEM., vol. 72, 2007, pages 23A - 24A
   SERAFIN ET AL., MINI REV. MED. CHEM., vol. 9, 2009, pages 481 - 497
   BIOCHEM., vol. 11, 1972, pages 942 - 944
   BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
   ANAND ET AL., EXPERT OPIN. BIOL. THER., vol. 2, 2002, pages 607 - 620
   HARPER, PROGRESS IN DRUG RESEARCH, vol. 4, 1962, pages 221 - 294
   GANGWAR ET AL., DES. BIOPHARM. PROP. PRODRUGS ANALOGS, 1977, pages 409 - 421
   BUNDGAARD, ARCH. PHARM. CHEM
   FARQUHAR ET AL., J. PHARM. SCI., vol. 72, 1983, pages 324 - 325
   WERNUTH ET AL.: "Drug Design: Fact or Fantasy", 1984, ACADEMIC PRESS, pages: 47 - 72
   FLEISHER ET AL., METHODS ENZYMOL., vol. 112, 1985, pages 360 - 381
   STELLA ET AL., DRUGS, vol. 29, 1985, pages 455 - 473
   BUNDGAARD, CONTROLLED DRUG DELIVERY, vol. 17, 1987, pages 179 - 96
   WALLER ET AL., BR. J. CLIN. PHARMAC., vol. 28, 1989
   BALANT ET AL., EUR. J. DRUG METAB. PHARMACOKINET., vol. 15, 1990, pages 143 - 53
   FREEMAN ET AL., J. CHEM. SOC., CHEM. COMMUN., 1991, pages 875 - 877
   BUNDGAARD, ADV. DRUG DELIVERY REV., vol. 8, 1992, pages 1 - 38
   NATHWANIWOOD, DRUGS, vol. 45, 1993, pages 866 - 94
   FRIISBUNDGAARD, EUR. J. PHARM. SCI., vol. 4, 1996, pages 49 - 59
   FLEISHER ET AL., ADV. DRUG DELIVERY REV., vol. 19, 1996, pages 131 - 148
   SINHABABUTHAKKER, ADV. DRUG DELIVERY REV, vol. 19, 1996, pages 241 - 273
   GAIGNAULT ET AL., PRACT. MED. CHEM., 1996, pages 671 - 696
   BROWNE, CLIN. NEUROPHARMACOL., vol. 20, 1997, pages 1 - 12
   VALENTINOBORCHARDT, DRUG DISCOVERY TODAY, vol. 2, 1997, pages 148 - 155
   PAULETTI ET AL., ADV. DRUG. DELIVERY REV., vol. 27, 1997, pages 235 - 256
   MIZEN ET AL., PHARM. BIOTECH., vol. 11, 1998, pages 345 - 365
   BALIMANESINKO, ADV. DRUG DELIVERY REV., vol. 39, 1999, pages 183 - 209
   WANG ET AL., CURR. PHARM. DESIGN, vol. 5, 1999, pages 265 - 287
   HAN ET AL., AAPS PHARMSCI., vol. 2, 2000, pages 1 - 11
   VERMA ET AL., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 26, 2000, pages 695 - 708
   SINHA ET AL., PHARM. RES., vol. 18, 2001, pages 557 - 564
   RAO, RESONACE, 2003, pages 19 - 27
   SLOAN ET AL., MED. RES. REV., vol. 23, 2003, pages 763 - 793
   PATTERSON ET AL., CURR. PHARM. DES., vol. 9, 2003, pages 2131 - 2154
   HU, IDRUGS, vol. 7, 2004, pages 736 - 742
   ROBINSON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 101, 2004, pages 14527 - 14532
   FANG ET AL., CURR. DRUG DISCOV. TECHNOL., vol. 3, 2006, pages 211 - 224
   STANCZAK ET AL., PHARMACOL. REP., vol. 58, 2006, pages 599 - 613
   SLOAN ET AL., PHARM. RES., vol. 23, 2006, pages 2729 - 2747
   STELLA ET AL., ADV. DRUG DELIV. REV., vol. 59, 2007, pages 677 - 694
   GOMES ET AL., MOLECULES, vol. 12, 2007, pages 2484 - 2506
   KRAFZ ET AL., CHEMMEDCHEM, vol. 3, 2008, pages 20 - 53
   RAUTIO ET AL., AAPS J, vol. 10, 2008, pages 92 - 102
   RAUTIO ET AL., NAT. REV. DRUG. DISCOV., vol. 7, 2008, pages 255 - 270
   SANDROS ET AL., MOLECULES, vol. 13, 2008, pages 2136 - 2155
   HUTTUNEN ET AL., CURR. MED. CHEM., vol. I5, 2008, pages 2346 - 2365
   CONWAY, RECENT PAT. DRUG DELIV. FORMUL., vol. 2, 2008, pages 1 - 8
   BUSSEMER ET AL., CRIT. REV. THER. DRUG CARRIER SYST., vol. 18, 2001, pages 433 - 458
   MARONI ET AL., EXPERT. OPIN. DRUG DELIV., vol. 2, 2005, pages 855 - 871
   SHI ET AL., EXPERT OPIN. DRUG DELIV., vol. 2, 2005, pages 1039 - 1058
   "Polymers in Drug Delivery", 2006, CRC PRESS LLC
   BADAWY ET AL., J. PHARM. SCI., vol. 9, 2007, pages 948 - 959
   MODIFIED-RELEASE DRUG DELIVERY TECHNOLOGY
   GAZZANIGA ET AL., EUR. J. PHARM. BIOPHARM., vol. 68, 2008, pages 11 - 18
   NAGARWAL ET AL., CURR. DRUG DELIV., vol. 5, 2008, pages 282 - 289
   GALLARDO ET AL., PHARM. DEV. TECHNOL., vol. 13, 2008, pages 413 - 423
   CHRZANOWSKI, AAPS PHARMSCITECH., vol. 9, 2008, pages 635 - 638
   CHRZANOWSKI, AAPS PHARMSCITECH, vol. 9, 2008, pages 639 - 645
   KALANTZI ET AL., RECENT PAT. DRUG DELIV. FORMUL., vol. 3, 2009, pages 64 - 70
   ROY ET AL., J. CONTROL RELEASE, vol. 134, 2009, pages 74 - 80
   TAKADA ET AL.: "Encyclopedia of Controlled Drug Delivery", vol. 2, 1999, WILEY
   SANTUSBAKER, J. CONTROLLED RELEASE, vol. 35, 1995, pages 1 - 21
   VERMA ET AL., J. CONTROLLED RELEASE, vol. 79, 2002, pages 7 - 27
   MULTIPARTICULATE ORAL DRUG DELIVERY, 1994
   "Pharmaceutical Pelletization Technology", 1989, MARCEL DEKKER
   FISHMAN ET AL.: "Medicine", 1985, J.B. LIPPINCOTT CO.
   PHILADELPHIAMURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC.
   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
   JOURNAL OF BIOLOGICAL CHEMISTRY
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.